$RLYB SEC Filings

Filed On	Filing
27 Oct 2026	10-Q
26 Oct 2026	425
26 Oct 2026	8-K: Other Events As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delawa...
20 Oct 2026	Form 4: Soteropoulos Paula, Director Received 3,562 shares by exercise or conversion ($8.48K)
20 Oct 2026	Form 4: Boudreau Helen M, Director Received 2,062 shares by exercise or conversion ($31.5K)
15 Oct 2026	EFFECT
15 Oct 2026	424B3
14 Oct 2026	Form 4: Hopfner Robert Lorne, Director Received 14,820 shares by exercise or conversion ($110K)
14 Oct 2026	S-4/A NO. 4
13 Oct 2026	Form 4: Lieber Jonathan I, Chief Financial Officer Received 3,910 shares by exercise or conversion ($23.8K)
08 Oct 2026	Form 4: Uden Stephen, Director Received 22,456 shares by exercise or conversion ($137K)
05 Oct 2026	S-4/A NO. 3
01 Oct 2026	Form 4: Lieber Jonathan I, Chief Financial Officer Received 5,000 shares by exercise or conversion ($30.4K)
28 Sep 2026	Form 4: Liu Hui, Director Received 12,044 shares by exercise or conversion ($72.9K)
18 Sep 2026	Form 4: Chung Wendy, Director Received 3,562 shares by exercise or conversion ($8.48K)
16 Sep 2026	S-4/A NO. 2
09 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation This letter agreement (this “Agreement”) is made and entered into as of this 8th day of September, 2026 (the “Effective Date”) by and among Rallybio Corporation (“Rallybio”), a Delaware corporation, Rallybio, LLC (“Rallybio LLC”), a Dela...
26 Aug 2026	S-4/A
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A

Comments